HK1237267B - 用放射、氧化鈰納米顆粒和化療劑的組合治療癌症 - Google Patents

用放射、氧化鈰納米顆粒和化療劑的組合治療癌症 Download PDF

Info

Publication number
HK1237267B
HK1237267B HK17111200.4A HK17111200A HK1237267B HK 1237267 B HK1237267 B HK 1237267B HK 17111200 A HK17111200 A HK 17111200A HK 1237267 B HK1237267 B HK 1237267B
Authority
HK
Hong Kong
Prior art keywords
radiation
cancer
cerium oxide
effective dose
oxide nanoparticles
Prior art date
Application number
HK17111200.4A
Other languages
German (de)
English (en)
French (fr)
Other versions
HK1237267A1 (zh
Inventor
Cheryl BAKER
Original Assignee
BioCurity Pharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BioCurity Pharmaceuticals Inc. filed Critical BioCurity Pharmaceuticals Inc.
Publication of HK1237267A1 publication Critical patent/HK1237267A1/zh
Publication of HK1237267B publication Critical patent/HK1237267B/zh

Links

HK17111200.4A 2014-07-17 2015-07-17 用放射、氧化鈰納米顆粒和化療劑的組合治療癌症 HK1237267B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462025861P 2014-07-17

Publications (2)

Publication Number Publication Date
HK1237267A1 HK1237267A1 (zh) 2018-04-13
HK1237267B true HK1237267B (zh) 2021-03-12

Family

ID=

Similar Documents

Publication Publication Date Title
EP3169312B1 (en) Treatment of cancer with a combination of radiation, cerium oxide nanoparticles, and a chemotherapeutic agent
JP2020158507A6 (ja) 放射線、酸化セリウムナノ粒子、及び化学療法剤の併用によるがんの治療
Zhao et al. The clinical development of MEK inhibitors
Cheng et al. Targeting MAPK pathway in melanoma therapy
EP3750530B1 (en) Combinations of irs/stat3 dual modulators and anti-cancer agents for treating cancer
JP6911047B2 (ja) がんの処置のための、Ｎｏｔｃｈ阻害剤およびＣＤＫ４／６阻害剤の併用療法
JP2024526155A (ja) Ｅｒｋ１／２およびｓｈｐ２阻害剤の併用療法
Aoki et al. Oral-recombinant methioninase converts an osteosarcoma from docetaxel-resistant to-sensitive in a clinically-relevant patient-derived orthotopic-xenograft (PDOX) mouse model
JP6911048B2 (ja) がんの処置において使用するための、Ｎｏｔｃｈ阻害剤およびＰＩ３Ｋ／ｍＴＯＲ阻害剤を用いた併用療法
TWI873485B (zh) 用於治療癌症之方法及包含cdk2抑制劑及cdk4抑制劑之給藥方案
CN107427522A (zh) 用于治疗黑素瘤的阿吡莫德
JP2014515390A (ja) Ｐｉ３ｋ阻害剤化合物を用いた中皮腫の治療法
WO2011017809A1 (en) Autophagy inhibitor compounds, compositions and methods for the use thereof in the treatment of cancer
Qiang et al. Targeting the PI3K/AKT/mTOR pathway in lung cancer: mechanisms and therapeutic targeting
US11389536B2 (en) Treatment of cancer with a combination of radiation, cerium oxide nanoparticles, and a chemotherapeutic agent
Odhiambo et al. Preclinical evaluation of the ATR inhibitor BAY 1895344 as a radiosensitizer for head and neck squamous cell carcinoma
HK40026959A (zh) 一種治療癌症的輻射、氧化鈰納米顆粒和化學治療劑
HK1237267B (zh) 用放射、氧化鈰納米顆粒和化療劑的組合治療癌症
HK1237267A1 (zh) 用放射、氧化鈰納米顆粒和化療劑的組合治療癌症
김유석 Anti-tumor Effects of the Tyrosine Kinase Inhibitor Rivoceranib in Canine Melanoma and Mammary Gland Tumor
Dębska-Szmich et al. Clinical use of cyclin-dependent kinase (CDK) 4/6 inhibitors in patients with breast cancer—literature review
Cazzanelli et al. Colorectal Cancer Therapeutic Approaches: From Classical Drugs to New Nanoparticles
WO2025181652A1 (en) Treatment of cancer using aripiprazole and anticancer agent
KR20220140723A (ko) 암의 치료를 위한 약제학적 조합
Dreyling A closer look at copanlisib